GeneReach Biotechnology (4171) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GeneReach Biotechnology (4171) has a cash flow conversion efficiency ratio of 0.020x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$12.05 Million ≈ $379.64K USD) by net assets (NT$596.72 Million ≈ $18.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 4171 days of operational coverage to measure how many days the company can operate on defensive assets alone.
GeneReach Biotechnology - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how GeneReach Biotechnology's cash flow conversion efficiency has evolved over time, based on yearly financial data.
GeneReach Biotechnology Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GeneReach Biotechnology ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zedge Inc
NYSE MKT:ZDGE
|
0.026x |
|
GoviEx Uranium Inc
V:GXU
|
-0.236x |
|
Ihuman Inc
NYSE:IH
|
0.193x |
|
Iljin Display
KO:020760
|
-0.010x |
|
Axe Compute Inc.
NASDAQ:AGPU
|
-0.078x |
|
Elcomtec Co. Ltd
KQ:037950
|
0.006x |
|
FORCS Co.Ltd
KQ:189690
|
0.034x |
|
US Global Investors Inc
NASDAQ:GROW
|
0.006x |
Annual Cash Flow Conversion Efficiency for GeneReach Biotechnology (2017–2025)
The table below shows the annual cash flow conversion efficiency of GeneReach Biotechnology from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of GeneReach Biotechnology.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$596.72 Million ≈ $18.80 Million |
NT$-13.52 Million ≈ $-425.80K |
-0.023x | +29.25% |
| 2024-12-31 | NT$725.49 Million ≈ $22.86 Million |
NT$-23.22 Million ≈ $-731.68K |
-0.032x | +28.61% |
| 2023-12-31 | NT$862.44 Million ≈ $27.17 Million |
NT$-38.67 Million ≈ $-1.22 Million |
-0.045x | -113.83% |
| 2022-12-31 | NT$1.10 Billion ≈ $34.74 Million |
NT$357.63 Million ≈ $11.27 Million |
0.324x | +1.12% |
| 2021-12-31 | NT$1.09 Billion ≈ $34.28 Million |
NT$348.99 Million ≈ $11.00 Million |
0.321x | +62.01% |
| 2020-12-31 | NT$857.76 Million ≈ $27.02 Million |
NT$169.82 Million ≈ $5.35 Million |
0.198x | +1148.98% |
| 2019-12-31 | NT$593.05 Million ≈ $18.68 Million |
NT$-11.19 Million ≈ $-352.64K |
-0.019x | -202.24% |
| 2018-12-31 | NT$311.15 Million ≈ $9.80 Million |
NT$5.74 Million ≈ $180.97K |
0.018x | +167.78% |
| 2017-12-31 | NT$250.63 Million ≈ $7.90 Million |
NT$-6.83 Million ≈ $-215.06K |
-0.027x | -- |
About GeneReach Biotechnology
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers various equipment, such as POCKIT Central Nucleic Acid Analyzer, POCKIT Micro Series, taco mini Automatic Nucleic Acid Extraction System, taco Prep Homogenization System, and cubee Mini-Centrifuge; reagents and consumables, including Human IVD Assa… Read more